



November 1, 2021

Web Announcement 2624

Silver State Scripts Board (SSSB) Approves Changes to Preferred Drug List (PDL) Effective November 1, 2021

The Nevada Silver State Scripts Board (SSSB) met on July 29, 2021, and voted to adopt the following changes effective November 1, 2021.

The complete Preferred Drug List (PDL) is posted on the ["Preferred Drug List"](#) webpage.

Drug Class/Program	Changes
Analgesics – Opiate Agonists	Hydrocodone bitartrate added as non-preferred.
Analgesics – Opiate Agonists - Abuse Deterrent	Embeda®, MorphaBond® and Arymo® ER removed from PDL. Hydrocodone bitartrate added as non-preferred.
Cardiovascular Agents – Antilipemics – PCSK9 Inhibitors (NEW)	Praluent® and Repatha® added as preferred.
Dermatological Agents – Topical Anti-Infectives – Topical Scabicides	Ivermectin topical added as non-preferred.
Gastrointestinal Agents – Functional Gastrointestinal Disorder Drugs	Lubiprostone added as non-preferred.
Neurological Agents – Anti-Migraine Agents – CGRP Receptor Antagonists	Vyepti® added as non-preferred.
Ophthalmic Agents – Antiglaucoma Agents	Brimonidine moved to non-preferred and Brinzolamide added as non-preferred.
Psychotropic Agents – Antipsychotics – Atypical Antipsychotics – Oral/Topical	Asenapine added as non-preferred. Invega® added as preferred.